Möller H J, Kissling W, Dietzfelbinger T, Stoll K D, Wendt G
Department of Psychiatry, Technical University, Munich, FRG.
Pharmacopsychiatry. 1989 Jan;22(1):38-41. doi: 10.1055/s-2007-1014575.
Savoxepine is a new tetracyclic compound displaying potent neurolepticlike effects in pharmacological studies. Of particular interest is its preferential binding to dopamine-2 receptors in the hippocampus, which leads to the hypothesis that savoxepine may exert antipsychotic effects at doses not inducing extrapyramidal side-effects. In an open pilot-study 18 patients suffering from acute schizophrenic psychoses or paranoid syndromes were treated with savoxepine in an individually adapted dose range from 0.50 to 10 mg per day. A good antipsychotic efficacy could be demonstrated in 10 of 16 patients. Savoxepine was found to be generally well tolerated. Contrary to expectations, mild or moderate extrapyramidal side-effects, especially of the parkinsonian type, were registered. Future research has to test the suggested advantage of savoxepine in comparison with other neuroleptic drugs.
沙沃西平是一种新型四环化合物，在药理学研究中显示出强效的类抗精神病作用。特别值得关注的是它在海马体中对多巴胺-2受体的优先结合，这引发了一种假说，即沙沃西平可能在不诱发锥体外系副作用的剂量下发挥抗精神病作用。在一项开放性初步研究中，18例患有急性精神分裂症性精神病或偏执综合征的患者接受了沙沃西平治疗，剂量根据个体情况调整，范围为每天0.50至10毫克。16例患者中有10例显示出良好的抗精神病疗效。结果发现沙沃西平总体耐受性良好。与预期相反，记录到了轻度或中度的锥体外系副作用，尤其是帕金森氏症类型的。未来的研究必须测试沙沃西平与其他抗精神病药物相比所具有的上述优势。
